Reference : The role of COX-2 in rectal cancer treated with preoperative radiotherapy
Scientific journals : Article
Human health sciences : Oncology
Human health sciences : Hematology
The role of COX-2 in rectal cancer treated with preoperative radiotherapy
Bouzourene, H. [ > > ]
Pu, Yan [Centre Hospitalier Universitaire Vaudois (Lausanne) > pathology > > >]
Sandmeier, Dominique [Centre Hospitalier Universitaire Vaudois (Lausanne) > pathology > > >]
Zouhair, Abderrahim [Centre Hospitalier Universitaire Vaudois (Lausanne) > radiooncology > > >]
Matter, Maurice [Centre Hospitalier Universitaire Vaudois (Lausanne) > Surgery > > >]
Vuilleumier, Henri [Centre Hospitalier Universitaire Vaudois (Lausanne) > Surgery > > >]
Coucke, Philippe mailto [hopital Maisonneuve-Rosemont (Canada) > Radiation-Oncology > > >]
Virchows Archiv : An International Journal of Pathology
Springer International
Yes (verified by ORBi)
[en] Rectal disease ; Cyclooxygenase 2 ; Rectum cancer ; Treatment ; Preoperative ; Radiotherapy ; Survival ; Relapse ; Anatomic pathology ; Oxidoreductases ; Enzyme ; Digestive diseases ; Intestinal disease ; Malignant tumor ; Cancer ; Anorectal disease
[fr] Pathologie du rectum ; Cyclooxygenase 2 ; Cancer du rectum ; Traitement ; Préopératoire ; Radiothérapie ; Survie ; Récidive ; Anatomopathologie ; Enzyme ; Pathologie de l'appareil digestif ; Pathologie de l'intestin ; Tumeur maligne ; Cancer ; Pathologie anorectale
[en] Radiotherapy is one of the principal modalities of rectal cancer treatment, and the ability to predict radio resistance could potentially improve survival through a targeted treatment approach. Cyclooxygenase-2 (COX-2) may protect against damage by irradiation that would justify the use of COX-2 inhibitors. The purpose of this study was to investigate the potential role of COX-2 in tumor response and outcome of patients with rectal cancer treated preoperatively with radiotherapy. Using immunohistochemistry, we examined COX-2 expression in 88 surgical specimens of rectal cancer treated preoperatively and in 26 pretherapeutic biopsies. We tested whether COX-2 expression was correlated with clinico-pathologic parameters and with survival and local recurrence. COX-2 was expressed in 50% of the pretherapeutic tumor biopsies and in 88.6% of post-irradiated surgical samples. COX-2 expression was correlated only with enhanced tumor inflammation (p=0.03) and with tumor volume exceeding 30 cc (p=0.05). COX-2 was not significantly correlated with patient survival, but none of the patients with COX-2 negative tumors did recur locally, whereas 80% of patients with local recurrences have COX-2 positive tumors. We conclude that COX-2 expression is overexpressed in the majority of rectal cancers treated with radiotherapy and likely plays a role in local relapse.
Researchers ; Professionals ; Students ; General public ; Others

File(s) associated to this reference

Fulltext file(s):

Open access
The role of COX-2 in rectal cancer treated with preoperative radiotherapy.pdfPublisher postprint207.11 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.